Categories
Resource Centre - Media & Press

Next Generation Pathogen Genome Sequencing Trainings in Bangladesh

Bangladeshi scientists participate in next generation genome sequencing of SARS-CoV-2 genome

In November 2022, The Child Health Research Foundation (CHRF) of Bangladesh announced that, for the first time, the SARS-CoV-2 genome was sequenced at the Next generation sequencing Research and Innovation Lab, Chittagong (NRICh). CHRF stated, “With support from our friends at FIND, CHRF helped set up the lab and provided training for its members. We will continue decentralising genomics and building scientists for Bangladesh.”

Read more about this achievement here

Categories
Add Resources - Scaling Up & Sustainability

WHO webinar on genomic surveillance and SARS-CoV-2 sequencing capacity

In this webinar, WHO and FIND co-host a discussion on sequencing capacity for SARS-CoV-2 and global initiatives to strengthen genomic surveillance.

Co-chaired by Natacha Milhano, WHO Public Health Laboratory Strengthening Unit, and Dr Dhamari Naidoo, WHO South-East Asia, it featured the following speakers and topics:

  • Dr Lisa Carter: Genomic surveillance strategy for pathogens with epidemic or pandemic potential
  • Dr Anita Suresh: Mapping and building genomic surveillance capacity for COVID-19 and beyond
  • Dr Senjuti Saha: Towards building capacity and accelerating genomic surveillance: one step at a time 
  • Dr Sikhulile Moyo: Pathogen genomics of SARS-CoV-2: Lessons from Botswana.

Participants shared learnings from the experiences of Botswana (Moyo) and Bangladesh (Saha) on building next generation sequencing capacity, and the global strategy launched by WHO on 31 March 2022 (Carter).

The presentation on 20 April 2022 was in English, with simultaneous interpretations in Arabic, French, Portuguese, Russian and Spanish.

Watch the webinar on YouTube

Categories
Add Resources - Scaling Up & Sustainability

FIND partners with CSIR-IGIB to strengthen SARS-CoV-2 genomic surveillance in India

FIND has partnered with CSIR-IGIB (Institute of Genomics and Integrated Biology) to help India fight COVID-19 by boosting sequencing capacity across the country. 

The partnership aims to decentralize genomic surveillance of SARS-CoV-2 by setting up “MicroLabs”. These will enable sequencing, analysis and interpretation of sequencing data with minimal turnaround time and infrastructure limited settings.

The goal is to optimize and scale the capacity needed to identify SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI).

The partnership will also  identify genomic hotspots and mutations associated with disease severity that are critical for surveillance and public health action.

Read the report here

Categories
Add Resources - Quality Assurance & Policy

Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–2032

Looking at the decade 2022-2032, WHO presents a global genomic surveillance strategy for pathogens with pandemic and epidemic potential.

The goal is to strengthen and scale surveillance of these pathogens to enable quality, timely and appropriate public health actions across local to global surveillance systems.

WHO’s strategy outlines five objectives with accompanying actions that need implementation plans.

It also highlights considerations to build global genomic surveillance over the next 10 years, as well as monitoring and evaluation mechanisms.

The report includes two annexes:

  • Strategy development and stakeholder engagement
  • Key WHO assets for the strategy.

Read report here

Categories
Add Resources - Quality Assurance & Policy

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 8 January 2021

WHO released its publication, Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, on 8 January 2021.

As the genomes of SARS-CoV-2 are able to be sequenced almost within real time, this enables increased speed to inform public health responses.

This has led to more laboratories investing in viral genome sequencing. Before starting such a programme, however, the intended goals of sequencing must be understood and a strategy for analysis in place, as well as a plan for how findings will be used.

Decisions about sequencing goals should be made in a multidisciplinary framework that includes representatives of all stakeholders. Funding sources must also be identified, and ethical aspects evaluated.

To maximize public health impact, usable and timely results need to be produced and communicated.

This document, available in English and Portuguese, provides this type of guidance for laboratories on maximizing the impact of SARS-CoV-2 sequencing activities now and in the future.

Read the guide here


Categories
Resource Centre - Publications

SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?

The global COVID-19 pandemic continues due to emerging Severe Acute Respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC). Here, we performed comprehensive analysis of in-house sequenced SARS-CoV-2 genome mutations dynamics in the patients infected with the VOCs – Delta and Omicron, within Recovered and Mortality patients. Statistical analysis highlighted significant mutations – T4685A, N4992N, and G5063S in RdRp; T19R in NTD spike; K444N and N532H in RBD spike, associated with Delta mortality. Mutations, T19I in NTD spike, Q493R and N440K in the RBD spike were significantly associated with Omicron mortality. We performed molecular docking for possible effect of significant mutations on the binding of Remdesivir. We found that Remdesivir showed less binding efficacy with the mutant Spike protein of both Delta and Omicron mortality compared to recovered patients. This indicates that mortality associated mutations could have a modulatory effect on drug binding which could be associated with disease outcome.

Download Document


Categories
Resource Centre - Publications

Mutational dynamics across VOCs in International travellers and Community transmission underscores importance of Spike-ACE2 interaction

Highlights

  • The mutational landscape of 1567 international travellers and community transmission were characterized across VOCs in India
  • Mutations in LD for VOCs demonstrated differentially altered binding affinity and electrostatic interactions of Spike-ACE2.•
  • Altered Spike-ACE2 affinity among VOCs predicted sudden takeover of Delta over Alpha and BA.2 over BA.1 in India.

Download Document


Categories
Resource Centre - Publications

SARS-CoV-2 Variants of Concern and Variations within Their Genome Architecture: Does Nucleotide Distribution and Mutation Rate Alter the Functionality and Evolution of the Virus?

SARS-CoV-2 virus pathogenicity and transmissibility are correlated with the mutations acquired over time, giving rise to variants of concern (VOCs). Mutations can significantly influence the genetic make-up of the virus. Herein, we analyzed the SARS-CoV-2 genomes and sub-genomic nucleotide composition in relation to the mutation rate. Nucleotide percentage distributions of 1397 in-house-sequenced SARS-CoV-2 genomes were enumerated, and comparative analyses (i) within the VOCs and of (ii) recovered and mortality patients were performed. Fisher’s test was carried out to highlight the significant mutations, followed by RNA secondary structure prediction and protein modeling for their functional impacts. Subsequently, a uniform dinucleotide composition of AT and GC was found across study cohorts. Notably, the N gene was observed to have a high GC percentage coupled with a relatively higher mutation rate. Functional analysis demonstrated the N gene mutations, C29144T and G29332T, to induce structural changes at the RNA level. Protein secondary structure prediction with N gene missense mutations revealed a differential composition of alpha helices, beta sheets, and coils, whereas the tertiary structure displayed no significant changes. Additionally, the N gene CTD region displayed no mutations. The analysis highlighted the importance of N protein in viral evolution with CTD as a possible target for antiviral drugs.

Download Document


Categories
Resource Centre - Publications

100,000 genomes – in Africa, for Africa

Visit Website


Categories
Resource Centre - Publications

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

The past 2 years, during which waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants swept the globe, have starkly highlighted health disparities across nations. Tegally et al. show how the coordinated efforts of talented African scientists have in a short time made great contributions to pandemic surveillance and data gathering. Their efforts and initiatives have provided early warning that has likely benefited wealthier countries more than their own. Genomic surveillance identified the emergence of the highly transmissible Beta and Omicron variants and now the appearance of Omicron sublineages in Africa. However, it is imperative that technology transfer for diagnostics and vaccines, as well the logistic wherewithal to produce and deploy them, match the data-gathering effort. —CA

Visit Website